RenovoRx (NASDAQ:RNXT – Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Monday, Wall Street Zen reports.
Separately, Weiss Ratings raised shares of RenovoRx from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, September 2nd. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, RenovoRx currently has an average rating of “Moderate Buy” and a consensus target price of $8.50.
Get Our Latest Stock Report on RNXT
RenovoRx Price Performance
Shares of RNXT stock opened at $1.18 on Monday. The stock has a 50-day simple moving average of $1.52 and a 200 day simple moving average of $1.11. RenovoRx has a fifty-two week low of $0.70 and a fifty-two week high of $2.59.
RenovoRx (NASDAQ:RNXT – Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.01). RenovoRx had a negative return on equity of 133.49% and a negative net margin of 469.02%. The business had revenue of $1.07 million during the quarter, compared to the consensus estimate of $1.06 million. On average, equities research analysts anticipate that RenovoRx will post -0.28 EPS for the current year.
Institutional Investors Weigh In On RenovoRx
A hedge fund recently bought a new position in RenovoRx stock. T3 Companies LLC acquired a new position in shares of RenovoRx, Inc. (NASDAQ:RNXT – Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 96,800 shares of the company’s stock, valued at approximately $151,000. T3 Companies LLC owned approximately 0.21% of RenovoRx as of its most recent SEC filing. 3.10% of the stock is currently owned by hedge funds and other institutional investors.
Key Stories Impacting RenovoRx
Here are the key news stories impacting RenovoRx this week:
- Neutral Sentiment: A short-interest update reported zero shares short and a 0.0-day short-interest ratio. That suggests no reported short position, although the accompanying description of an increase conflicts with the figure. [No article link provided]
- Negative Sentiment: HC Wainwright cut its estimates for RenovoRx’s losses in several coming quarters and fiscal years. Its FY2026 forecast worsened to a $0.29-per-share loss from $0.21, while its FY2027 estimate shifted to a $0.19 loss from $0.04. The firm also reduced its projected profits for FY2029 and FY2030, implying a later path to profitability than previously expected. HC Wainwright Estimates RenovoRx’s Q4 Earnings
- Negative Sentiment: Wall Street Zen lowered its rating on RNXT to “Sell,” adding to the cautious analyst sentiment. RenovoRx Rating Lowered to Sell at Wall Street Zen
RenovoRx Company Profile
RenovoRx, Inc. is a clinical-stage biopharmaceutical company developing targeted treatments for solid tumors. The company’s approach is based on its Trans-Arterial Micro-Perfusion (TAMP) platform, which is designed to deliver chemotherapy directly into tumor tissue through the arterial system while limiting exposure to surrounding healthy tissue. RenovoRx’s lead investigational product, RenovoCath, is a localized drug-delivery system intended to support the administration of anticancer therapies to tumors.
Featured Articles
- Five stocks we like better than RenovoRx
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Receive News & Ratings for RenovoRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RenovoRx and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}
